about
Cholecalciferol and Cancer: Is It a Big D3-eal?Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysisEffects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors"Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.Clinical characteristics and outcomes of cancer patients with post-chemotherapy arthritis: a retrospective case series report.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.The association between breast cancer prognostic indicators and serum 25-OH vitamin D levelsProspective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.The effect of various vitamin D supplementation regimens in breast cancer patients.Clinical Significance of Female-hormones and Cytokines in Breast Cancer Patients Complicated with Aromatase Inhibitor-related Osteoarthropathy - Efficacy of Vitamin E.Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for managementTreatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side studyAromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expressionPatterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.Anastrozole-associated joint pain and other symptoms in patients with breast cancer.A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.Breast cancer survivorship symptom management: current perspective and future development.Progression of endocrine therapies for breast cancer: where are we headed?Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapyAromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.The expanding use of third-generation aromatase inhibitors: what the general internist needs to knowAn evaluation of lower-body functional limitations among long-term survivors of 11 different types of cancers.Challenges in clinical patient management.Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.Individualization of treatment strategies.A prospective model of care for breast cancer rehabilitation: bone health and arthralgias.When are breast cancer patients old enough for the quitclaim of local control?Safety of aromatase inhibitor therapy in breast cancer.Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment.Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.
P2860
Q26852226-7180D167-A2AB-4346-8757-2CC82EBAA63FQ28087204-A6A5DC7D-A9C6-4145-A893-712C43EA3AD2Q33647466-102030F9-D700-4E0F-B2A7-4265CD7DF45EQ33714141-71BA3196-9B0C-4B7A-A00C-6F2048CA91BCQ33756757-CB606FB0-E55D-4331-AB22-F0F97DBCE499Q33768811-287D4FED-F951-4A05-B35F-738D127CB0B5Q33793932-762EA49D-83A6-4C30-920A-EB51CA579CD4Q34024686-A245A4C2-3056-469B-ADE1-C6DE19A59F06Q34143532-8950F656-5609-40A3-B7F0-B39923404FD8Q34153722-E5410C6A-3302-4DB6-8EEC-BB31ED9BAAD7Q34847405-73E27DFD-2A66-4B15-8596-F4C968383BEBQ34893987-7839D1C1-0D1F-4EEA-9D88-3611818A19EDQ35148098-D726E051-629D-4D0A-A948-2B7D2B620DDFQ35558893-73B23A95-CA75-4F7A-B9F9-2EA4EC6248A3Q35687540-DA7426F6-8C39-483E-A7A9-0D2C66B9BD7AQ35742012-B605BB12-19BC-44E8-8327-805024707B02Q35914925-8D731F17-07C9-4D65-92E0-DA35F432416CQ36095985-F3D72D78-755C-4841-AE67-A92C4426AAD6Q36245513-EBCDD12D-5779-4335-A685-49F510F4DC83Q36601787-2FF1D395-7AAB-44C8-82AE-76EEFC1732CEQ36655900-C85EAB12-3D9E-4426-B92F-E88FCFD22822Q36675274-9779BFF3-45FB-4F5F-A39F-ECD1BDE3DC49Q36876171-BBCF3237-E5E5-416F-91A7-C8D769982FBCQ36941450-EB35B5ED-00A3-456C-A2D7-A30EDA658168Q36956837-B7492DEA-2F0D-495F-BD5E-D78521B90097Q37004695-5FE016C6-1890-457C-9809-87F04E2C98CCQ37165933-EC93793E-C6AE-4B49-8864-5ED9E724D048Q37193002-C151598E-DE2D-4047-A0E0-3EF9F6829942Q37390076-AB17C219-8386-42DF-86EA-606581360B6BQ37468783-FE32A2CB-9557-460F-BC31-4F93BC888C03Q37775020-0D83EC07-4FD4-47B2-8B59-227F837B8124Q37830371-935A2460-84D1-4D3A-A6CF-2B51F67F653DQ37933161-F1092DD7-EACD-4166-9F2D-C42E6755B9C6Q38001377-3C76E060-B24B-42E3-9F25-454B95E07B76Q38056081-A828B324-DD1B-40A4-9D6B-8A65FD51EBF8Q38522924-05379BC2-96B0-4CBF-B669-4DA98ED22D1AQ38963111-2BF14A04-1326-443B-ACD9-F0242CAE58FAQ39323459-A915F673-6716-4C50-ABB7-89B407E26E16Q42632584-2432FFF0-2494-4357-AC00-4FD0A7A00C1CQ43567721-F377C678-120D-45BD-8B93-8A83C051DDF3
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Aromatase inhibitor-associated arthralgia syndrome.
@ast
Aromatase inhibitor-associated arthralgia syndrome.
@en
type
label
Aromatase inhibitor-associated arthralgia syndrome.
@ast
Aromatase inhibitor-associated arthralgia syndrome.
@en
prefLabel
Aromatase inhibitor-associated arthralgia syndrome.
@ast
Aromatase inhibitor-associated arthralgia syndrome.
@en
P1433
P1476
Aromatase inhibitor-associated arthralgia syndrome.
@en
P2093
Harold J Burstein
P304
P356
10.1016/J.BREAST.2007.01.011
P577
2007-03-21T00:00:00Z